Medline Inc. (MDLN) valuation against sector peers: P/B 4.4, EV/EBIT 39.6, free-cash-flow yield 3.6%, P/S 1.7.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.

Metric	MDLN	Sector median	vs median
P/E	—	29.2 · n=157	—
P/B	4.4	3.8 · n=307	16% above
P/S	1.7	4.1 · n=300	58% below
EV/EBIT	39.6	25.6 · n=145	54% above
Free-cash-flow yield	3.6%	1.5% · n=289	145% above
Dividend yield	0.00%	0.00% · n=362	—
Return on equity	—	−2.4% · n=306	—
Return on invested capital	6.1%	0.6% · n=280	853% above
Gross margin	25.7%	63.3% · n=205	59% below
Net debt / EBITDA	3.30	1.30 · n=150	154% above

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.

Sector peers

The largest companies of the same sector and region.

Instrument	P/E	P/B	EV/EBIT	Free-cash-flow yield	Dividend yield	Smart Score
LLYEli Lilly & Co	46.2	31.6	—	1.5%	0.6%	6/10
JNJJohnson & Johnson	41.3	8.2	—	3.1%	1.9%	8/10
ABBVAbbVie	50.0	—	27.6	3.7%	2.9%	6/10
MRKMerck	147.5	8.1	—	4.1%	2.3%	8/10
UNHUnitedHealth	22.2	3.4	16.9	6.5%	2.3%	10/10
TMOThermo Fisher Scientific	36.4	4.7	34.5	3.0%	0.3%	9/10
AMGNAmgen	26.5	17.4	23.0	3.8%	2.2%	8/10
GILDGilead Sciences	—	15.9	—	6.7%	1.9%	4/10
ABTAbbott	40.5	3.7	32.8	3.5%	2.8%	6/10
PFEPfizer	41.5	1.9	—	7.0%	7.3%	1/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 26 Sep 2026 · filed 04 Nov 2026

Withdraw from contract here · EU consumers: 14 days to withdraw from a purchase.

Cookie settings